,

(Obesity
Society)
(American
Society for Metabolic and Bariatric Surgery),
15 2014. Journal
of Clinical Endocrinology and Metabolism.


.
:
1,

2.

:
;
;

;
.
. 1 .

1.0.

1.1. ,


() 25
/2, ( 27
/2
30 /2)
( 35 /2

40 /2),

,

, .


,

,
.
,
, ,

,
(1
).
1.2.


w w w.reproduc t-endo.com.ua

1.



-4

-
-

**

-
*

Caroline M.
Apovian

, ,
,

Louis J. Aronne

,
-,

Daniel H. Bessesen

, , ,

Marie E. McDonnell

,
, ,

M. Hassan Murad

,
, ,

Uberto Pagotto

, ,

Donna H. Ryan

,
-, ,

Christopher D.
Still

, ,
,

.
**
.

(Food and Drug Administration,
FDA)
(European Medicines Agency,
EMA) (
),

.


30 /2 27 /2,


, ,
2- (-2),
(2
).

/ w w w.reproduc t-endo.com 3 (23) / 2015

ISSN 2309-4117

59


1.3.


1 (1
).
1.4.
,
,
3 , 3
(2
).
1.5. ,
, ( 5%
3 .) ,
.
( < 5% 3 .)
,
,


(1
).
1.6.

,

,
,

(2
).
1.7. -2,
,
,
,
(, 1-
[GLP-1] - -
2- [SGLT-2]),
-2 (2
).
1.8. -
, ,
,
(2
).
. 2 3

. . 4
,
,
.

2. ,

($)

*
*
+
**

**

()
**
()

($)
*

**

**

**
($$$)

($$$)
*

*


($$)
($$$)

23%; 35%; 5% 3 .
**
12 .

3.

-2

, , (. .).

60

3 (23) / 2015 w ww.reproduc t-endo.com / w w w.reproduc t-endo.com.ua

ISSN 2309-4117

/ w w w.reproduc t-endo.com 3 (23) / 2015

ISSN 2309-4117

() +
()

(10 )

(60 )

(120 )

61

6,6 (14,5 )
( ), 6,6%.
8,6 (18,9 ) (
), 8,6%; 1 .

4,8%; 1 .

5,8 ; 1 .

()

().

1.

3,6 (7,9 ), 3,6%; 1 .

2,93,4 (6,57,5 ),
2,93,4%; 1 .

2,93,4 (6,57,5 ),
2,93,4%; 1 .

3,0 (6,6 );
652 .

3,6 (7,9 );
224 .

-
()

().

52.

FDA 2014 .

.

FDA 2014 .

.

FDA 2012 .

.

FDA 2012 .

.

FDA 1999 .

.

FDA 1999 .

.

FDA 1960 .

(3 ).

1960 .

(3 ).

FDA

* .

3,0 .

32 / 360 2
4 / ( ).

3,75 / 23 ,

1 /
( ).
7,5 / 46 ,

( ).
15 / 92 / T


( ).

10 2 /.

60120 3 /.

120 3 /.

(75 ),
75 /.

-
(37,5 ),
37,5 /.
(30 ),
30-37,5 /.

4. ( 2014 .)


,
()

(%
*),

w w w.reproduc t-endo.com.ua

, , .

, , , , .

, , , , ,
.

, , , ,
, .

. .

,
2-
.

,
,
,
, .

,
, , ,
.

.
:

/
, , , ,
.

. .

, , ( 2
), ,
,
,
, ,
, .
, , ,
.

. .

( ),
- ,
,
,
(),
, ,
,
, .

, ,
, ,
, , .
- : , ,
, .
:
, , , ,
, , , , .
-: , ,
, , - .
: .
: , .
. .


2.0.
2.1. -2,
,

.

, ,

,
(1
).
2.2. , -2
,

: , GLP-1,
,
.
.

. ,



(2
).
2.3.
,
,
-
-2,
(1
).
2.4. ,


,
.
,
,
(1
).
2.5.

, ,
,

,

(1
).
2.6.

, ,

,

(1
).
2.7. > 27 /2
> 30 /2,
,
,
-
.

62

(,
) (2
).
2.8.
,
,

- (2
).
2.9.
, ,


, ,

(2
).
2.10.

( ),
(2
).
3.0.
,

3.1. ,

, .
,
,
,
(,
, Best Practice
Recommendation).

http://press.endocrine.org/doi/full/10.1210/jc.2014-3415

3 (23) / 2015 w ww.reproduc t-endo.com / w w w.reproduc t-endo.com.ua

ISSN 2309-4117

Caroline M. Apovian, , , ,
Louis J. Aronne, - , -,
Daniel H. Bessesen, , , ,
Marie E. McDonnell, , , ,
M. Hassan Murad, , , ,
Uberto Pagotto, , ,
Donna H. Ryan, , -, ,
Christopher D. Still, , , ,
: .
: .
.
: , ,
(GRADE), .
: .
, , ,
. , , , ,
, , . ,
. , .
: , , , , .

Caroline M. Apovian, , , ,
Louis J. Aronne, - , -,
Daniel H. Bessesen, ', , ,
Marie E. McDonnell, , , ,
M. Hassan Murad, , , ,
Uberto Pagotto, , ,
Donna H. Ryan, , -, ,
Christopher D. Still, ' , , ,
: .
: . .
: (GRADE),
.
: ' . ,
, ,
. , , , ,
. , , , . ,
' .
: , , , , .
PHARMACOLOGICAL MANAGEMENT OF OBESITY
AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE

Caroline M. Apovian, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts
Louis J. Aronne, Weill-Cornell Medical College, New York, New York
Daniel H. Bessesen, Denver Health Medical Center, Denver, Colorado
Marie E. McDonnell, Brigham and Womens Hospital, Boston, Massachusetts
M. Hassan Murad, Mayo Clinic, Division of Preventative Medicine, Rochester, Minnesota
Uberto Pagotto, Alma Mater University of Bologna, Bologna, Italy
Donna H. Ryan, Pennington Biomedical Research Center, Baton Rouge, Louisiana
Christopher D. Still, Geisinger Health Care System, Danville, Pennsylvania
Objective: To formulate clinical practice guidelines for the pharmacological management of obesity.
Participants: An Endocrine Society-appointed Task Force of experts. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society.
Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of
recommendations and the quality of evidence.
Conclusions: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management
can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other
chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight
profiles, can aid in the prevention and management of obesity and thus improve health.
Keywords: overweight, obesity, obesity pharmacotherapy, clinical management, Endocrine Society.

w w w.reproduc t-endo.com.ua

/ w w w.reproduc t-endo.com 3 (23) / 2015

ISSN 2309-4117

63